Claims

1. *N,N-bis*-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceutically-acceptable salt and/or derivative thereof, for use in the treatment or prevention of paracetamol toxicity.

2. The use of *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, for the manufacture of a medicament for the treatment or prevention of paracetamol toxicity.

3. A method for the treatment or prevention of paracetamol toxicity, which method comprises the administration of an effective amount of *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, to a patient in need thereof.

4. *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, for use in the treatment or prevention of acute liver failure associated with paracetamol toxicity.

5. The use *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, for the manufacture of a medicament for the treatment or prevention of acute liver failure associated with paracetamol toxicity.

6. A method for the treatment or prevention of acute liver failure associated with paracetamol toxicity, which method comprises the administration of an effective amount of *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, to a patient in need thereof.

7. A pharmaceutical formulation comprising:

(a) *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof; and

(b) one or more other therapeutic agent that is useful in the treatment or prevention of paracetamol toxicity,

and optionally one or more pharmaceutically-acceptable excipients.

8. A kit-of-parts comprising components:

(A) a pharmaceutical formulation comprising *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, and optionally one or more pharmaceutically-acceptable excipients; and

(B) a pharmaceutical formulation comprising one or more other therapeutic agent that is useful in the treatment or prevention of paracetamol toxicity, and optionally one or more pharmaceutically-acceptable excipients,

which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.

9. A pharmaceutical formulation comprising:

(a) *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof; and

(b) paracetamol,

and optionally one or more pharmaceutically-acceptable excipients.

10. A kit-of-parts comprising components:

(A) a pharmaceutical formulation comprising *N,N-bis*-2-mercaptoethyl isophthalamide, or a pharmaceutically-acceptable salt and/or derivative thereof, and optionally one or more pharmaceutically-acceptable excipients; and

(B) a pharmaceutical formulation comprising paracetamol, and optionally one or more pharmaceutically-acceptable excipients,

which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.

11. A compound for use, use, method, pharmaceutical formulation for use, combination product or kit-of-parts substantially as described herein, with reference to the examples.